Efficacy of methylprednisolone pulse therapy for acute relapse in Japanese patients with multiple sclerosis and neuromyelitis optica: A multicenter retrospective analysis - 1. Whole group analysis

Jun-Ichi Kira, Ryo Yamasaki, Satoshi Yoshimura, Toshiyuki Fukazawa, Kazumasa Yokoyama, Kazuo Fujihara, Mieko Ogino, Takanori Yokota, Katsuichi Miyamoto, Masaaki Niino, Kyoichi Nomura, Ryo Tomioka, Masami Tanaka, Izumi Kawachi, Takashi Ohashi, Kenichi Kaida, Makoto Matsui, Yuji Nakatsuji, Hirofumi Ochi, Hikoaki FukauraTakashi Kanda, Akiko Nagaishi, Kanae Togo, Hidehiro Mizusawa, Yuji Kawano

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objectives There has been no large-scale study of methylprednisolone pulse therapy in Asian patients with multiple sclerosis (MS) or neuromyelitis optica (NMO), despite it being widely used for acute relapse. We aimed to clarify treatment response of MS and NMO patients to methylprednisolone pulse therapy and post-pulse oral corticosteroids in real clinical practice in a multicenter study in Japan. Methods Investigators at 28 institutions collected changes in neurological symptoms/signs and Expanded Disability Status Scale (EDSS) scores before and within 1 week of completion of methylprednisolone pulse therapy carried out in 2010, and after post-pulse oral corticosteroids therapy, by retrospective review of medical records. Results In 345 patients (95.1% of all registered patients), 457 series of methylprednisolone pulse therapy were carried out for treatment of acute relapse. EDSS scores improved by 0.8 ± 1.1 (mean ± SD) after the first course. The second and third courses also produced sufficient improvements (by 0.7 and 0.6, respectively), but much smaller improvements were observed thereafter. The target neurological symptoms and signs improved in 79.5% of patients. Improvement rates were 5-20% lower after a course of pulse therapy than after a series of pulse therapy. A half dose (500 mg/day) produced less improvement than a standard dose (1000 mg/day; 65.9 vs 79.5%). During post-pulse oral corticosteroid therapy, EDSS scores decreased by 0.6 ± 0.9. No significant adverse effects were observed. Conclusions Methylprednisolone pulse therapy is beneficial in nearly 80% of Japanese MS and NMO patients, and EDSS score improvements after therapy are compatible with those in Western MS patients.

Original languageEnglish
Pages (from-to)305-317
Number of pages13
JournalClinical and Experimental Neuroimmunology
Volume4
Issue number3
DOIs
Publication statusPublished - Dec 1 2013

Fingerprint

Neuromyelitis Optica
Methylprednisolone
Multiple Sclerosis
Recurrence
Therapeutics
Adrenal Cortex Hormones
Signs and Symptoms
Multicenter Studies
Medical Records

All Science Journal Classification (ASJC) codes

  • Neuroscience (miscellaneous)
  • Immunology
  • Immunology and Microbiology (miscellaneous)
  • Clinical Neurology

Cite this

Efficacy of methylprednisolone pulse therapy for acute relapse in Japanese patients with multiple sclerosis and neuromyelitis optica : A multicenter retrospective analysis - 1. Whole group analysis. / Kira, Jun-Ichi; Yamasaki, Ryo; Yoshimura, Satoshi; Fukazawa, Toshiyuki; Yokoyama, Kazumasa; Fujihara, Kazuo; Ogino, Mieko; Yokota, Takanori; Miyamoto, Katsuichi; Niino, Masaaki; Nomura, Kyoichi; Tomioka, Ryo; Tanaka, Masami; Kawachi, Izumi; Ohashi, Takashi; Kaida, Kenichi; Matsui, Makoto; Nakatsuji, Yuji; Ochi, Hirofumi; Fukaura, Hikoaki; Kanda, Takashi; Nagaishi, Akiko; Togo, Kanae; Mizusawa, Hidehiro; Kawano, Yuji.

In: Clinical and Experimental Neuroimmunology, Vol. 4, No. 3, 01.12.2013, p. 305-317.

Research output: Contribution to journalArticle

Kira, J-I, Yamasaki, R, Yoshimura, S, Fukazawa, T, Yokoyama, K, Fujihara, K, Ogino, M, Yokota, T, Miyamoto, K, Niino, M, Nomura, K, Tomioka, R, Tanaka, M, Kawachi, I, Ohashi, T, Kaida, K, Matsui, M, Nakatsuji, Y, Ochi, H, Fukaura, H, Kanda, T, Nagaishi, A, Togo, K, Mizusawa, H & Kawano, Y 2013, 'Efficacy of methylprednisolone pulse therapy for acute relapse in Japanese patients with multiple sclerosis and neuromyelitis optica: A multicenter retrospective analysis - 1. Whole group analysis', Clinical and Experimental Neuroimmunology, vol. 4, no. 3, pp. 305-317. https://doi.org/10.1111/cen3.12071
Kira, Jun-Ichi ; Yamasaki, Ryo ; Yoshimura, Satoshi ; Fukazawa, Toshiyuki ; Yokoyama, Kazumasa ; Fujihara, Kazuo ; Ogino, Mieko ; Yokota, Takanori ; Miyamoto, Katsuichi ; Niino, Masaaki ; Nomura, Kyoichi ; Tomioka, Ryo ; Tanaka, Masami ; Kawachi, Izumi ; Ohashi, Takashi ; Kaida, Kenichi ; Matsui, Makoto ; Nakatsuji, Yuji ; Ochi, Hirofumi ; Fukaura, Hikoaki ; Kanda, Takashi ; Nagaishi, Akiko ; Togo, Kanae ; Mizusawa, Hidehiro ; Kawano, Yuji. / Efficacy of methylprednisolone pulse therapy for acute relapse in Japanese patients with multiple sclerosis and neuromyelitis optica : A multicenter retrospective analysis - 1. Whole group analysis. In: Clinical and Experimental Neuroimmunology. 2013 ; Vol. 4, No. 3. pp. 305-317.
@article{ecf3de6da6a84981a47bbd1484673b6a,
title = "Efficacy of methylprednisolone pulse therapy for acute relapse in Japanese patients with multiple sclerosis and neuromyelitis optica: A multicenter retrospective analysis - 1. Whole group analysis",
abstract = "Objectives There has been no large-scale study of methylprednisolone pulse therapy in Asian patients with multiple sclerosis (MS) or neuromyelitis optica (NMO), despite it being widely used for acute relapse. We aimed to clarify treatment response of MS and NMO patients to methylprednisolone pulse therapy and post-pulse oral corticosteroids in real clinical practice in a multicenter study in Japan. Methods Investigators at 28 institutions collected changes in neurological symptoms/signs and Expanded Disability Status Scale (EDSS) scores before and within 1 week of completion of methylprednisolone pulse therapy carried out in 2010, and after post-pulse oral corticosteroids therapy, by retrospective review of medical records. Results In 345 patients (95.1{\%} of all registered patients), 457 series of methylprednisolone pulse therapy were carried out for treatment of acute relapse. EDSS scores improved by 0.8 ± 1.1 (mean ± SD) after the first course. The second and third courses also produced sufficient improvements (by 0.7 and 0.6, respectively), but much smaller improvements were observed thereafter. The target neurological symptoms and signs improved in 79.5{\%} of patients. Improvement rates were 5-20{\%} lower after a course of pulse therapy than after a series of pulse therapy. A half dose (500 mg/day) produced less improvement than a standard dose (1000 mg/day; 65.9 vs 79.5{\%}). During post-pulse oral corticosteroid therapy, EDSS scores decreased by 0.6 ± 0.9. No significant adverse effects were observed. Conclusions Methylprednisolone pulse therapy is beneficial in nearly 80{\%} of Japanese MS and NMO patients, and EDSS score improvements after therapy are compatible with those in Western MS patients.",
author = "Jun-Ichi Kira and Ryo Yamasaki and Satoshi Yoshimura and Toshiyuki Fukazawa and Kazumasa Yokoyama and Kazuo Fujihara and Mieko Ogino and Takanori Yokota and Katsuichi Miyamoto and Masaaki Niino and Kyoichi Nomura and Ryo Tomioka and Masami Tanaka and Izumi Kawachi and Takashi Ohashi and Kenichi Kaida and Makoto Matsui and Yuji Nakatsuji and Hirofumi Ochi and Hikoaki Fukaura and Takashi Kanda and Akiko Nagaishi and Kanae Togo and Hidehiro Mizusawa and Yuji Kawano",
year = "2013",
month = "12",
day = "1",
doi = "10.1111/cen3.12071",
language = "English",
volume = "4",
pages = "305--317",
journal = "Clinical and Experimental Neuroimmunology",
issn = "1759-1961",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Efficacy of methylprednisolone pulse therapy for acute relapse in Japanese patients with multiple sclerosis and neuromyelitis optica

T2 - A multicenter retrospective analysis - 1. Whole group analysis

AU - Kira, Jun-Ichi

AU - Yamasaki, Ryo

AU - Yoshimura, Satoshi

AU - Fukazawa, Toshiyuki

AU - Yokoyama, Kazumasa

AU - Fujihara, Kazuo

AU - Ogino, Mieko

AU - Yokota, Takanori

AU - Miyamoto, Katsuichi

AU - Niino, Masaaki

AU - Nomura, Kyoichi

AU - Tomioka, Ryo

AU - Tanaka, Masami

AU - Kawachi, Izumi

AU - Ohashi, Takashi

AU - Kaida, Kenichi

AU - Matsui, Makoto

AU - Nakatsuji, Yuji

AU - Ochi, Hirofumi

AU - Fukaura, Hikoaki

AU - Kanda, Takashi

AU - Nagaishi, Akiko

AU - Togo, Kanae

AU - Mizusawa, Hidehiro

AU - Kawano, Yuji

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Objectives There has been no large-scale study of methylprednisolone pulse therapy in Asian patients with multiple sclerosis (MS) or neuromyelitis optica (NMO), despite it being widely used for acute relapse. We aimed to clarify treatment response of MS and NMO patients to methylprednisolone pulse therapy and post-pulse oral corticosteroids in real clinical practice in a multicenter study in Japan. Methods Investigators at 28 institutions collected changes in neurological symptoms/signs and Expanded Disability Status Scale (EDSS) scores before and within 1 week of completion of methylprednisolone pulse therapy carried out in 2010, and after post-pulse oral corticosteroids therapy, by retrospective review of medical records. Results In 345 patients (95.1% of all registered patients), 457 series of methylprednisolone pulse therapy were carried out for treatment of acute relapse. EDSS scores improved by 0.8 ± 1.1 (mean ± SD) after the first course. The second and third courses also produced sufficient improvements (by 0.7 and 0.6, respectively), but much smaller improvements were observed thereafter. The target neurological symptoms and signs improved in 79.5% of patients. Improvement rates were 5-20% lower after a course of pulse therapy than after a series of pulse therapy. A half dose (500 mg/day) produced less improvement than a standard dose (1000 mg/day; 65.9 vs 79.5%). During post-pulse oral corticosteroid therapy, EDSS scores decreased by 0.6 ± 0.9. No significant adverse effects were observed. Conclusions Methylprednisolone pulse therapy is beneficial in nearly 80% of Japanese MS and NMO patients, and EDSS score improvements after therapy are compatible with those in Western MS patients.

AB - Objectives There has been no large-scale study of methylprednisolone pulse therapy in Asian patients with multiple sclerosis (MS) or neuromyelitis optica (NMO), despite it being widely used for acute relapse. We aimed to clarify treatment response of MS and NMO patients to methylprednisolone pulse therapy and post-pulse oral corticosteroids in real clinical practice in a multicenter study in Japan. Methods Investigators at 28 institutions collected changes in neurological symptoms/signs and Expanded Disability Status Scale (EDSS) scores before and within 1 week of completion of methylprednisolone pulse therapy carried out in 2010, and after post-pulse oral corticosteroids therapy, by retrospective review of medical records. Results In 345 patients (95.1% of all registered patients), 457 series of methylprednisolone pulse therapy were carried out for treatment of acute relapse. EDSS scores improved by 0.8 ± 1.1 (mean ± SD) after the first course. The second and third courses also produced sufficient improvements (by 0.7 and 0.6, respectively), but much smaller improvements were observed thereafter. The target neurological symptoms and signs improved in 79.5% of patients. Improvement rates were 5-20% lower after a course of pulse therapy than after a series of pulse therapy. A half dose (500 mg/day) produced less improvement than a standard dose (1000 mg/day; 65.9 vs 79.5%). During post-pulse oral corticosteroid therapy, EDSS scores decreased by 0.6 ± 0.9. No significant adverse effects were observed. Conclusions Methylprednisolone pulse therapy is beneficial in nearly 80% of Japanese MS and NMO patients, and EDSS score improvements after therapy are compatible with those in Western MS patients.

UR - http://www.scopus.com/inward/record.url?scp=84890830651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890830651&partnerID=8YFLogxK

U2 - 10.1111/cen3.12071

DO - 10.1111/cen3.12071

M3 - Article

AN - SCOPUS:84890830651

VL - 4

SP - 305

EP - 317

JO - Clinical and Experimental Neuroimmunology

JF - Clinical and Experimental Neuroimmunology

SN - 1759-1961

IS - 3

ER -